$VIVS News

VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling

VivoSim Labs To Extend Its Human Tissue Platform Beyond Toxicology With Efficacy Testing Services Built On NAMkind Disease Models Of The Liver And Intestine

VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods

Vivosim Labs Notes FDA's Direct Final Rule Clarifying That Non-Animal Methods Can Be Used Where Appropriate For Testing Safety Of Drugs And Biological Products For Human Use

VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs

VivoSim Labs to Add Rat Liver Model to NAMkind Platform

VivoSim Labs Plans To Develop Rat Liver Model To Complement Existing NAMkind Human Liver Platform And Expand Its Liver Toxicology Capabilities

VivoSim Labs Receives Nasdaq Noncompliance Notice, Gets Time Through Sept. 3 To Regain Compliance

VivoSim Reports First Commercial Sales in China for NAMkind Testing Services (NASDAQ:VIVS)

VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services

VivoSim Labs Announces First Commercial Sales In China For Its NAMkind Testing Services

VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor

Why Is VivoSim Labs Stock Falling Thursday?

VivoSim Labs Prices ~$4M Private Placement Of Common Stock, Pre-Funded Warrants At Combined Price Of $0.85/Share, Accompanying Warrant

VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting

VivoSim Labs To Present Data Demonstrating Its 3D Human Tissue Models In Two Presentations At The European Society Of Toxicology Annual Conference

VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing

VivoSim Announces Pricing of up to a $4 Million Public Offering

VivoSim Labs shares are trading lower after the company announced that it priced a $4 million public offering.

VivoSim Labs shares are trading lower after the company announced that it priced a $4 million public offering.